Combination pathogenetic therapy for psoriasis: relief of inflammation and correction of metabolic disorders
- Authors: Piruzyan A.1, Denisova E.2,1, Dvoryankova E.1, Denieva M.3, Sobolev V.1, Korsunskaya I.2,1
-
Affiliations:
- Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
- Moscow Research and Practical Center for Dermatovenereology and Cosmetology
- Republican Dermatovenereology Dispensary
- Issue: Vol 30, No 10 (2019)
- Pages: 32-35
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114079
- DOI: https://doi.org/10.29296/25877305-2019-10-06
- ID: 114079
Cite item
Open Access
Access granted
Abstract
Psoriasis is an autoimmune inflammatory disease that is characterized by a predominant skin lesion and has a complex pathogenesis. The current scientific concept of the pathogenesis of this dermatosis gives pride of place in its development to immune-mediated inflammation, the main mechanism of which is immune cell dysfunction. In addition, systemic and local dyslipidemia can cause inflammation. Immunoinflammatory responses and lipid profile disorders are currently considered as promising therapeutic targets for psoriasis. The authors’ own observations show that the inclusion of drugs that can affect both inflammation and lipid profile (glycyrrhizic acid and essential phospholipids) in the combination therapy of psoriasis makes it possible not only to normalize the blood levels of total cholesterol, triglycerides and other lipids, but also to more quickly get significant regression results in skin rashes.
Full Text
About the authors
A. Piruzyan
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
E. Denisova
Moscow Research and Practical Center for Dermatovenereology and Cosmetology; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
E. Dvoryankova
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
M. Denieva
Republican Dermatovenereology Dispensary
Email: marykor@bk.ru
V. Sobolev
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
I. Korsunskaya
Moscow Research and Practical Center for Dermatovenereology and Cosmetology; Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
References
- Gudjonsson J., Elder J. Psoriasis. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. Vol. 1 / New York: McGraw-Hill, 2008; pp. 169-93.
- Schon M. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders // Front Immunol. - 2019; 10: 1764. doi: 10.3389/fimmu.2019.01764.
- Fuchs J., Zollner T., Kaufmann R. et al. Redox-modulated pathways in inflammatory skin diseases // Free Radic. Biol. Med. - 2001; 30 (4): 337-53.
- Trouba K., Hamadeh H., Amin R. et al. Oxidative stress and its role in skin disease // Antioxid. Redox. Signal. - 2002; 4 (4): 665-73.
- Davidovici B., Sattar N., Prinz J. et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions // J. Invest. Dermatol. - 2010; 130 (7): 1785-96.
- Дворянкова Е.В., Пирузян А.Л., Соболев В.В. и др. Проблема дислипидемии в дерматологии // Эффективная фармакотерапия. - 2018; 21: 14-7
- Johnston A., Arnadottir S., Gudjonsson J. et al. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation // Br. J. Dermatol. - 2008; 159: 342-50.
- Ma C., Harskamp C., Armstrong E. et al. The association between psoriasis and dyslipidaemia: a systematic review // Br. J. Dermatol. - 2013; 168 (3): 486-95. doi: 10.1111/bjd.12101.
- Зыкова О.С., Соболевская И.С., Мяделец О.Д. и др. Морфологические особенности распределения свободного холестерола в эпидермисе при псориазе // Вестник Витебского Государственного Медицинского Университета. - 2012; 11 (1): 42-7
- Monteiro R., Azevedo I. Chronic inflammation in obesity and the metabolic syndrome // Mediators Inflamm. - 2010; 2010: 289645. doi: 10.1155/2010/289645.
- Корсунская И.М., Пирузян А.Л., Сакания Л.Р. и др. Роль глицирризиновой кислоты в патогенезе псориатической болезни // Эффективная фармакотерапия. - 2016; 13: 24-31
- Khunger N., Gupta D., Ramesh V. Is psoriasis a new cutaneous marker for metabolic syndrome? A study in Indian patients // Indian J. Dermatol. - 2013; 58: 313-4. doi: 10.4103/0019-5154.113958.
- Greenberg A., Obin M. Obesity and the role of adipose tissue in inflammation and metabolism // Am. J. Clin. Nutr. - 2006; 83 (2): 461S-5S. DOI: 10.1093/ ajcn/83.2.461S.
- Xu S., Zhang X., Pan M. et al. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis // Int. Immunopharmacol. - 2019; 75: 105841. doi: 10.1016/j.intimp.2019.105841.
- Clark C., Taghizadeh M., Nahavandi M. et al. Efficacy of ю-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials // Clin. Rheumatol. - 2019; 38 (4): 977-88. doi: 10.1007/s10067-019-04456-x.
- Zheng Q., Liang S., Xu F. et al. C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis // Front Immunol. - 2019; 10: 1866. DOI: 10.3389/ fimmu.2019.01866.
- Денисова Е.В., Дворянкова Е.В., Плиева К.Т. и др. Патологии гепатобилиарной системы у больных псориазом // Эффективная фармакотерапия. -2018; 21: 18-23
- Sahebkar A. Fat lowers fat: purified phospholipids as emerging therapies for dyslipidemia // Biochim. Biophys. Acta. - 2013; 1831 (4): 887-93. DOI: 10.1016/j. bbalip.2013.01.013.
- Egeberg A., Andersen Y., Halling-Overgaard A. et al. Systematic Review on Rapidity of Onset of Action for Interleukin-17 and Interleukin-23 Inhibitors for Psoriasis // J. Eur. Acad. Dermatol. Venereol. - 2019. doi: 10.1111/jdv.15920.
Supplementary files
